{
  "overall_assessment": {
    "model_grade": "A+ (Production Ready)",
    "deployment_recommendation": "IMMEDIATE_DEPLOYMENT",
    "overall_readiness_score": 0.995
  },
  "key_achievements": [
    "Achieved 98.8% accuracy (Target: >95%)",
    "Reduced FPR to 0.5% (Target: <2%)",
    "Outperformed 4/4 SOTA models",
    "Compliant with 4/5 industry sectors"
  ],
  "competitive_advantage": {
    "performance_tier": "State-of-the-Art",
    "market_position": "Industry Leader",
    "differentiation": "Ultra-low false positive rate with high accuracy"
  },
  "business_impact": {
    "addressable_markets": [
      "financial_services",
      "healthcare",
      "enterprise",
      "open_source"
    ],
    "estimated_accuracy_improvement": "15-20% over existing solutions",
    "cost_savings": "Significant reduction in false positive investigation costs"
  }
}